Third‑generation inhibitors targeting EGFR T790M mutation in non‑small cell lung cancer

01/2018

MUDr. Libor Havel

Pneumologická klinika 1. LF UK a Thomayerova nemocnice, Praha

SUMMARY

EGFR tyrosinkinase inhibitors became a cornerstone of therapy patients with advanced non-small cell lung cancer harbouring mutations in the EGFR kinase domain. EGFR TKI therapy is characterized by high response rate and prolonged progression free survival when compared with standard platinum-based chemotherapy dublets. Despite this, vast majority of patients develope during first 12 months of therapy resistence to TKI and tumor progression. The most common mechanism of this resistence is a secondary T790M mutation. EGFR TKI of third generation are deginged to overcome this type of resistence. Osimertinib became only one of these 3rd generation tyrosinkinase inhibitors adopted for clinical use. This paper will summarize data about 3rd generation EGFR TKI in the treatment of patients with non-small cell lung cancer.

KEY WORDS

non-small cell lung cancer, EGFR mutation, tyrosinkinase inhibitors, T790M